Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash from Financing Activities (2016 - 2025)

Corcept Therapeutics' Cash from Financing Activities history spans 10 years, with the latest figure at -$31.2 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 583.96% year-over-year to -$31.2 million; the TTM value through Dec 2025 reached -$220.4 million, down 677.33%, while the annual FY2025 figure was -$220.4 million, 677.33% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$31.2 million at Corcept Therapeutics, up from -$46.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $766000.0 in Q4 2023 and bottomed at -$207.0 million in Q4 2021.
  • The 5-year median for Cash from Financing Activities is -$17.5 million (2022), against an average of -$35.9 million.
  • The largest annual shift saw Cash from Financing Activities tumbled 31211.5% in 2021 before it soared 1355.74% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$207.0 million in 2021, then surged by 99.97% to -$61000.0 in 2022, then skyrocketed by 1355.74% to $766000.0 in 2023, then crashed by 695.82% to -$4.6 million in 2024, then tumbled by 583.96% to -$31.2 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Cash from Financing Activities are -$31.2 million (Q4 2025), -$46.4 million (Q3 2025), and -$102.9 million (Q2 2025).